Hengrui Pharma (Hengrui) and Braveheart Bio (Braveheart) today announced results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 study evaluating HRS-1893 (also known as ...
Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results